KR102358878B1 - 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법 - Google Patents

중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법 Download PDF

Info

Publication number
KR102358878B1
KR102358878B1 KR1020177037050A KR20177037050A KR102358878B1 KR 102358878 B1 KR102358878 B1 KR 102358878B1 KR 1020177037050 A KR1020177037050 A KR 1020177037050A KR 20177037050 A KR20177037050 A KR 20177037050A KR 102358878 B1 KR102358878 B1 KR 102358878B1
Authority
KR
South Korea
Prior art keywords
cells
cell
signaling
activator
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177037050A
Other languages
English (en)
Korean (ko)
Other versions
KR20180014743A (ko
Inventor
로렌즈 스튜더
스테판 이리온
마크 도미시마
손자 크릭스
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Priority to KR1020227003399A priority Critical patent/KR102679619B1/ko
Publication of KR20180014743A publication Critical patent/KR20180014743A/ko
Application granted granted Critical
Publication of KR102358878B1 publication Critical patent/KR102358878B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177037050A 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법 Active KR102358878B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003399A KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562169444P 2015-06-01 2015-06-01
US201562169379P 2015-06-01 2015-06-01
US62/169,444 2015-06-01
US62/169,379 2015-06-01
PCT/US2016/035312 WO2016196661A1 (en) 2015-06-01 2016-06-01 Methods of in vitro differentiation of midbrain dopamine (mda) neurons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003399A Division KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Publications (2)

Publication Number Publication Date
KR20180014743A KR20180014743A (ko) 2018-02-09
KR102358878B1 true KR102358878B1 (ko) 2022-02-08

Family

ID=57441792

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177037050A Active KR102358878B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020257025403A Pending KR20250118858A (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020247021208A Active KR102841407B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020227003399A Active KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257025403A Pending KR20250118858A (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020247021208A Active KR102841407B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020227003399A Active KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Country Status (18)

Country Link
US (3) US10858625B2 (https=)
EP (3) EP4070803B1 (https=)
JP (5) JP6974180B2 (https=)
KR (4) KR102358878B1 (https=)
AU (3) AU2016270793B2 (https=)
CY (1) CY1125423T1 (https=)
DK (2) DK4070803T3 (https=)
ES (2) ES2910032T3 (https=)
HR (1) HRP20220482T1 (https=)
HU (1) HUE058258T2 (https=)
IL (4) IL291532B2 (https=)
LT (1) LT3303564T (https=)
PL (1) PL3303564T3 (https=)
PT (2) PT3303564T (https=)
RS (1) RS63157B1 (https=)
SI (1) SI3303564T1 (https=)
SM (1) SMT202200263T1 (https=)
WO (1) WO2016196661A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6998772B2 (ja) * 2015-04-09 2022-02-04 ビオラミナ アーベー 神経変性疾患の処置における使用のための幹細胞由来のドパミン作用性細胞を生成するための方法および組成物
AU2016270793B2 (en) * 2015-06-01 2022-06-09 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (MDA) neurons
KR20180105236A (ko) * 2016-02-05 2018-09-27 메모리얼 슬로안-케터링 캔서 센터 줄기 세포-유래 외배엽 계통 전구체의 분화 방법
KR102625865B1 (ko) * 2016-08-16 2024-01-16 후지필름 셀룰러 다이내믹스, 인코포레이티드 만능 세포를 분화시키는 방법
KR20190141218A (ko) * 2017-04-26 2019-12-23 메모리얼 슬로안 케터링 캔서 센터 사용 준비된 냉동보존 세포
WO2019016113A1 (en) 2017-07-17 2019-01-24 Miltenyi Biotec Gmbh METHOD FOR PROFILING EXPRESSION OF UNICELLULAR PROTEIN FROM DOPAMINERGIC PROGENITOR CELLS OF MESENCEPHALIC FLOOR
WO2019032680A1 (en) * 2017-08-08 2019-02-14 Regents Of The University Of Minnesota METHODS OF GENERATING AND USING ORGANOIDS AND ASSOCIATED CELLS
JP2022514298A (ja) 2018-12-19 2022-02-10 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ オルガノイドおよびその組織を作製および使用するための方法
WO2020237104A1 (en) * 2019-05-23 2020-11-26 The Mclean Hospital Corporation Autologous cell replacement therapy for parkinson's disease
JP7810357B2 (ja) 2019-07-25 2026-02-03 ザ スクリプス リサーチ インスティテュート ドーパミン作動性ニューロン及び前駆細胞を特定する方法
EP4021477A4 (en) * 2019-08-29 2023-12-13 Memorial Sloan Kettering Cancer Center METHOD FOR GENERATING AND ISOLATING MID-DOPAMINE NEURONS
EP4032974A4 (en) * 2019-09-20 2023-12-06 Korea Research Institute of Bioscience and Biotechnology Production method for induced dopaminergic neuronal progenitors, using direct reprogramming
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
WO2021216623A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
US20250263752A1 (en) 2020-04-21 2025-08-21 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
US12104170B2 (en) * 2020-06-26 2024-10-01 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
CN116635047A (zh) * 2020-06-26 2023-08-22 米纳瓦生物技术公司 用于从多能干细胞衍生多巴胺能神经元的方法
CN114292814A (zh) * 2020-09-22 2022-04-08 上海跃赛生物科技有限公司 一种多能干细胞分化为中脑黒质多巴胺能神经细胞的方法
WO2022216911A1 (en) * 2021-04-07 2022-10-13 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
WO2023004370A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Aav-based modulation of gba1 and related compositions and uses thereof
WO2023004366A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
WO2023086894A1 (en) 2021-11-12 2023-05-19 Axent Biosciences Inc. Methods for production of functional neurons
WO2023201361A1 (en) 2022-04-15 2023-10-19 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells
US12565639B2 (en) * 2023-06-13 2026-03-03 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells
CN117448271B (zh) * 2023-12-22 2024-07-16 上海元戊医学技术有限公司 一种诱导多能干细胞分化为中脑多巴胺能神经前体细胞的方法
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture
WO2025252180A1 (zh) * 2024-06-05 2025-12-11 中国科学院脑科学与智能技术卓越创新中心 中脑多巴胺能祖细胞群的体外制备方法
WO2026006245A1 (en) 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067362A1 (en) 2011-11-04 2013-05-10 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
JP2014110790A (ja) 2000-05-17 2014-06-19 Asterious Biotherapeutics Inc 神経前駆細胞の集団
WO2015020234A1 (ja) 2013-08-06 2015-02-12 武田薬品工業株式会社 ドパミン神経細胞の製造方法
KR101696874B1 (ko) 2013-07-31 2017-01-16 한국생명공학연구원 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068431A2 (en) 1999-05-06 2000-11-16 Mount Sinai School Of Medicine Of New York University Dna-based steganography
EP1791949A2 (en) * 2004-09-02 2007-06-06 Neuro Therapeutics AB Methods and materials relating to enhanced production of dopamine neurons
WO2006071778A2 (en) * 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
JP5649786B2 (ja) 2006-03-07 2015-01-07 ギータ シュロフ ヒト胚性幹細胞およびそれらの誘導体を含む組成物、使用方法、ならびに調製方法
WO2008008266A2 (en) 2006-07-07 2008-01-17 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Biohybrid elastomeric scaffolds and methods of use thereof
WO2010096496A2 (en) 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
DK3578988T3 (da) 2010-05-25 2025-02-24 Memorial Sloan Kettering Cancer Center Fremgangsmåde til nociceptordifferentiering af humane embryonale stamceller og anvendelse heraf
US20110296542A1 (en) 2010-05-28 2011-12-01 Kevin Ka-Wang Wang Exogenous matrix-supported topical application of stem cells to organ surface
WO2013188744A1 (en) 2012-06-15 2013-12-19 Baylor College Of Medicine Perineurium derived adult stem cells and methods of use
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
AU2014316100B2 (en) * 2013-09-05 2020-11-05 Eisai R&D Management Co., Ltd. New method for inducing dopamine-producing neural precursor cells
AU2014352773B2 (en) 2013-11-21 2021-04-29 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
ES2939807T3 (es) * 2014-03-21 2023-04-27 Fujifilm Cellular Dynamics Inc Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización
AU2016270793B2 (en) * 2015-06-01 2022-06-09 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (MDA) neurons

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014110790A (ja) 2000-05-17 2014-06-19 Asterious Biotherapeutics Inc 神経前駆細胞の集団
WO2013067362A1 (en) 2011-11-04 2013-05-10 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
JP2014532440A (ja) 2011-11-04 2014-12-08 メモリアル スローン−ケタリング キャンサー センター 移植用中脳ドーパミン（ｄａ）ニューロン
KR101696874B1 (ko) 2013-07-31 2017-01-16 한국생명공학연구원 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법
WO2015020234A1 (ja) 2013-08-06 2015-02-12 武田薬品工業株式会社 ドパミン神経細胞の製造方法

Also Published As

Publication number Publication date
JP2018522538A (ja) 2018-08-16
DK3303564T3 (da) 2022-04-04
EP3303564B1 (en) 2022-02-23
KR20240101884A (ko) 2024-07-02
KR102679619B1 (ko) 2024-07-01
IL291532B2 (en) 2024-12-01
JP2023181494A (ja) 2023-12-21
AU2022228216B2 (en) 2026-02-19
JP2020146060A (ja) 2020-09-17
IL291532A (en) 2022-05-01
SI3303564T1 (sl) 2022-07-29
IL313799A (en) 2024-08-01
IL320440A (en) 2025-06-01
PL3303564T3 (pl) 2022-05-09
AU2016270793A1 (en) 2017-12-14
PT4070803T (pt) 2026-01-08
EP4070803A1 (en) 2022-10-12
HRP20220482T1 (hr) 2022-07-08
DK4070803T3 (da) 2026-01-12
AU2026200680A1 (en) 2026-02-19
JP2026015509A (ja) 2026-01-29
CY1125423T1 (el) 2024-12-13
WO2016196661A1 (en) 2016-12-08
EP4070803B1 (en) 2025-10-08
EP4079314A1 (en) 2022-10-26
KR102841407B1 (ko) 2025-08-01
SMT202200263T1 (it) 2022-07-21
US20240400987A1 (en) 2024-12-05
AU2016270793B2 (en) 2022-06-09
IL291532B1 (en) 2024-08-01
PT3303564T (pt) 2022-06-02
ES3057638T3 (en) 2026-03-03
IL255992A (en) 2018-01-31
IL255992B (en) 2022-04-01
KR20250118858A (ko) 2025-08-06
JP7737787B2 (ja) 2025-09-11
IL313799B1 (en) 2025-05-01
AU2022228216A1 (en) 2022-10-06
EP3303564A1 (en) 2018-04-11
JP6974180B2 (ja) 2021-12-01
HUE058258T2 (hu) 2022-07-28
JP2022031961A (ja) 2022-02-22
US20180094242A1 (en) 2018-04-05
IL313799B2 (en) 2025-09-01
ES2910032T3 (es) 2022-05-11
EP4079314B1 (en) 2025-10-29
KR20220020416A (ko) 2022-02-18
LT3303564T (lt) 2022-05-10
EP3303564A4 (en) 2018-10-31
RS63157B1 (sr) 2022-05-31
CA2987617A1 (en) 2016-12-08
KR20180014743A (ko) 2018-02-09
US10858625B2 (en) 2020-12-08
US12084679B2 (en) 2024-09-10
US20210123018A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
US20240400987A1 (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
CN114650836B (zh) 中脑多巴胺神经元的产生和分离方法
HK40082714A (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
HK40081864A (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
CA2987617C (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5